RATIONALE: The effect of stem/progenitor cells on myocardial perfusion and clinical outcomes in patients with refractory angina remains unclear because studies published to date have been small phase I-II trials. OBJECTIVE: We performed a meta-analysis of randomized controlled trials to evaluate the effect of cell-based therapy in patients with refractory angina who were ineligible for coronary revascularization. METHODS AND RESULTS: Several data sources were searched from inception to September 2015, which yielded 6 studies. The outcomes pooled were indices of angina (anginal episodes, Canadian Cardiovascular Society angina class, exercise tolerance, and antianginal medications), myocardial perfusion, and clinical end points. We combined the reported clinical outcomes (myocardial infarction, cardiac-related hospitalization, and mortality) into a composite end point (major adverse cardiac events). Mean difference (MD), standardized mean differences, or odds ratio were calculated to assess relevant outcomes. Our analysis shows an improvement in anginal episodes (MD, -7.81; 95% confidence interval [CI], -15.22 to -0.41), use of antianginal medications (standardized MD, -0.59; 95% CI, -1.03 to -0.14), Canadian Cardiovascular Society class (MD, -0.58; 95% CI, -1.00 to -0.16), exercise tolerance (standardized MD, 0.331; 95% CI, 0.08 to 0.55), and myocardial perfusion (standardized MD, -0.49; 95% CI, -0.76 to -0.21) and a decreased risk of major adverse cardiac events (odds ratio, 0.49; 95% CI, 0.25 to 0.98) and arrhythmias (odds ratio, 0.25; 95% CI, 0.06 to 0.98) in cell-treated patients when compared with patients on maximal medical therapy. CONCLUSIONS: The present meta-analysis indicates that cell-based therapies are not only safe but also lead to an improvement in indices of angina, relevant clinical outcomes, and myocardial perfusion in patients with refractory angina. These encouraging results suggest that larger, phase III randomized controlled trials are in order to conclusively determine the effect of stem/progenitor cells in refractory angina.
RATIONALE: The effect of stem/progenitor cells on myocardial perfusion and clinical outcomes in patients with refractory angina remains unclear because studies published to date have been small phase I-II trials. OBJECTIVE: We performed a meta-analysis of randomized controlled trials to evaluate the effect of cell-based therapy in patients with refractory angina who were ineligible for coronary revascularization. METHODS AND RESULTS: Several data sources were searched from inception to September 2015, which yielded 6 studies. The outcomes pooled were indices of angina (anginal episodes, Canadian Cardiovascular Society angina class, exercise tolerance, and antianginal medications), myocardial perfusion, and clinical end points. We combined the reported clinical outcomes (myocardial infarction, cardiac-related hospitalization, and mortality) into a composite end point (major adverse cardiac events). Mean difference (MD), standardized mean differences, or odds ratio were calculated to assess relevant outcomes. Our analysis shows an improvement in anginal episodes (MD, -7.81; 95% confidence interval [CI], -15.22 to -0.41), use of antianginal medications (standardized MD, -0.59; 95% CI, -1.03 to -0.14), Canadian Cardiovascular Society class (MD, -0.58; 95% CI, -1.00 to -0.16), exercise tolerance (standardized MD, 0.331; 95% CI, 0.08 to 0.55), and myocardial perfusion (standardized MD, -0.49; 95% CI, -0.76 to -0.21) and a decreased risk of major adverse cardiac events (odds ratio, 0.49; 95% CI, 0.25 to 0.98) and arrhythmias (odds ratio, 0.25; 95% CI, 0.06 to 0.98) in cell-treated patients when compared with patients on maximal medical therapy. CONCLUSIONS: The present meta-analysis indicates that cell-based therapies are not only safe but also lead to an improvement in indices of angina, relevant clinical outcomes, and myocardial perfusion in patients with refractory angina. These encouraging results suggest that larger, phase III randomized controlled trials are in order to conclusively determine the effect of stem/progenitor cells in refractory angina.
Authors: Douglas W Losordo; Timothy D Henry; Charles Davidson; Joon Sup Lee; Marco A Costa; Theodore Bass; Farrell Mendelsohn; F David Fortuin; Carl J Pepine; Jay H Traverse; David Amrani; Bruce M Ewenstein; Norbert Riedel; Kenneth Story; Kerry Barker; Thomas J Povsic; Robert A Harrington; Richard A Schatz Journal: Circ Res Date: 2011-07-07 Impact factor: 17.367
Authors: Benjamin Williams; Madhav Menon; Daniel Satran; Daniel Hayward; James S Hodges; M Nicholas Burke; Randall K Johnson; Anil K Poulose; Jay H Traverse; Timothy D Henry Journal: Catheter Cardiovasc Interv Date: 2010-05-01 Impact factor: 2.692
Authors: Emerson C Perin; Guilherme V Silva; Timothy D Henry; Maria G Cabreira-Hansen; Warren H Moore; Stephanie A Coulter; J Patrick Herlihy; Marlos R Fernandes; Benjamin Y C Cheong; Scott D Flamm; Jay H Traverse; Yi Zheng; Deirdre Smith; Sandi Shaw; Lynette Westbrook; Rachel Olson; Dipsu Patel; Amir Gahremanpour; John Canales; William K Vaughn; James T Willerson Journal: Am Heart J Date: 2011-05-10 Impact factor: 4.749
Authors: Evgeny Pokushalov; Alexander Romanov; Alexander Chernyavsky; Petr Larionov; Igor Terekhov; Sergey Artyomenko; Olga Poveshenko; Elena Kliver; Natalya Shirokova; Alexandr Karaskov; Nabil Dib Journal: J Cardiovasc Transl Res Date: 2009-09-24 Impact factor: 4.132
Authors: E Marc Jolicoeur; E Magnus Ohman; Robert Temple; Norman Stockbridge; Sidney Smith; Daniel Mark; Robert M Califf; Timothy D Henry; Bernard R Chaitman; Christopher B Granger Journal: Am Heart J Date: 2008-01-31 Impact factor: 4.749
Authors: Jan van Ramshorst; Jeroen J Bax; Saskia L M A Beeres; Petra Dibbets-Schneider; Stijntje D Roes; Marcel P M Stokkel; Albert de Roos; Willem E Fibbe; Jaap J Zwaginga; Eric Boersma; Martin J Schalij; Douwe E Atsma Journal: JAMA Date: 2009-05-20 Impact factor: 56.272
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Rahman Shah; Samuel B Latham; Sajjad A Khan; Muhammad Shahreyar; Inyong Hwang; Ion S Jovin Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882
Authors: Lilian Grigorian Shamagian; Rosalinda Madonna; Doris Taylor; Andreu M Climent; Felipe Prosper; Luis Bras-Rosario; Antoni Bayes-Genis; Péter Ferdinandy; Francisco Fernández-Avilés; Juan Carlos Izpisua Belmonte; Valentin Fuster; Roberto Bolli Journal: Circ Res Date: 2019-03-15 Impact factor: 17.367
Authors: Nilson T Poppi; Luís H W Gowdak; Luciana O C Dourado; Eduardo L Adam; Thiago N P Leite; Bruno M Mioto; José E Krieger; Luiz A M César; Alexandre C Pereira Journal: Clin Cardiol Date: 2016-10-18 Impact factor: 2.882